CA
DMAAR

Crossingbridge Advisors’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Crossingbridge Advisors’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-850,000
Closed -$106K – 103
2025
Q2 		$106K Hold
850,000
– – 0.09% 64
2025
Q1 		$807K Buy
+850,000
New +$119K 0.42% 44

Other funds holding DMAAR

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
HCI
Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Crossingbridge Advisors's DMAAR Position: Q3 2025 in Review

Crossingbridge Advisors sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q3 2025, closing a stake of 850,000 shares — an estimated $106K sold.

Crossingbridge Advisors first reported a position in DMAAR in Q1 2025 and held it in 2 quarters. The position peaked at $807K in Q1 2025. 32 funds tracked by Wall St. Rank hold DMAAR as of Q3 2025.

  • Crossingbridge Advisors reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q3 2025 after selling out during the quarter.
  • Crossingbridge Advisors sold 850,000 Drugs Made In America Acquisition Corp Rights shares in Q3 2025, an estimated $106K.
  • Crossingbridge Advisors first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 2 quarters.
  • Crossingbridge Advisors's Drugs Made In America Acquisition Corp Rights position peaked at $807K in Q1 2025.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q3 2025.

Based on Crossingbridge Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.